Canavan disease

Mendelian MONDO:0010079 Pathograph 34 Leukodystrophy

Canavan disease is an autosomal recessive leukodystrophy caused by biallelic pathogenic variants in ASPA, encoding aspartoacylase. Aspartoacylase deficiency impairs hydrolysis of N-acetyl-L-aspartate to acetate and aspartate, leading to NAA accumulation in the central nervous system and body fluids, spongiform white-matter degeneration, dysmyelination, severe infantile-onset neurodevelopmental impairment, macrocephaly, tone abnormalities, visual impairment, feeding difficulty, and progressive neurologic disability.

Ask OpenScientist

Ask a research question about Canavan disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Inheritance
9
Pathophys.
19
Phenotypes
34
Pathograph
1
Genes
3
Treatments
2
Trials
16
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0010079 Canavan disease
skos:exactMatch Orphanet ORPHA:141
Orphanet ORPHA:141 lists MONDO:0010079 as an exact cross-reference for Canavan disease.
📘

Definitions

1
Orphanet Canavan disease definition
A neurodegenerative disorder ranging from severe leukodystrophy with macrocephaly and severe developmental delay to very rare mild/juvenile disease with milder developmental delay.
OTHER
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"neurodegenerative disorder; its spectrum varies between severe forms with leukodystrophy"
Orphanet defines Canavan disease as a spectrum neurodegenerative leukodystrophy.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Canavan disease is inherited in an autosomal recessive pattern.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:141 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance for Canavan disease.
PMID:20301412 SUPPORT Other
"Canavan disease is inherited in an autosomal recessive manner."
GeneReviews confirms autosomal recessive inheritance.
⚙

Pathophysiology

9
ASPA variant protein destabilization
Many disease-linked ASPA missense variants destabilize the aspartoacylase protein, promoting misfolding and proteasomal degradation and thereby reducing active enzyme abundance.
ASPA link
protein folding link ⚠ ABNORMAL
Downstream
Aspartoacylase enzyme deficiency Destabilized ASPA variants reduce functional aspartoacylase activity.
Show evidence (1 reference)
PMID:38582917 SUPPORT Other
"most disease linked ASPA gene variants lead to a structural destabilization"
Recent review supports ASPA protein destabilization as a common mechanism.
Aspartoacylase enzyme deficiency
Loss of ASPA activity impairs the cytosolic/oligodendroglial hydrolysis of N-acetyl-L-aspartate to acetate and aspartate, initiating the core biochemical disease cascade.
oligodendrocyte link
ASPA link
N-acetylaspartate/aspartate metabolism link ⚠ ABNORMAL
aspartoacylase activity link ↓ DECREASED
cytosol link
Downstream
NAA accumulation in CNS and body fluids Failure to catabolize NAA causes substrate accumulation.
Reduced NAA-derived acetate and myelin lipid synthesis Loss of NAA hydrolysis limits acetate availability for myelin lipid synthesis.
Show evidence (2 references)
PMID:38582917 SUPPORT Other
"deficiency of the cytosolic aspartoacylase (ASPA) enzyme"
Mechanistic review directly identifies aspartoacylase deficiency.
PMID:15784740 SUPPORT Model Organism
"ASPA acts to hydrolyze N-acetylaspartate (NAA) into l-aspartate and acetate"
Mouse model study describes the enzymatic reaction blocked in Canavan disease.
NAA accumulation in CNS and body fluids
Aspartoacylase deficiency causes N-acetyl-L-aspartate to accumulate in the brain, urine, blood, cerebrospinal fluid, and other body fluids. Elevated urinary NAA and brain NAA by proton magnetic resonance spectroscopy are key diagnostic biochemical markers.
Downstream
Spongiform white-matter vacuolation High CNS NAA contributes to intramyelinic and white-matter vacuolation.
Neuronal loss and cortical thinning Model data link excess NAA to neuronal loss and cortical atrophy.
Elevated urinary N-acetylaspartic acid Elevated urinary NAA is a diagnostic readout of systemic NAA accumulation.
Elevated brain NAA by proton MR spectroscopy Elevated brain NAA by MRS is a diagnostic readout of CNS NAA accumulation.
Show evidence (2 references)
PMID:8412017 SUPPORT Human Clinical
"Deficiency of the enzyme aspartoacylase and the accumulation of N-acetylaspartic acid"
Biochemical study supports the enzyme-substrate defect.
PMID:34011350 SUPPORT Human Clinical
"loss of ASPA activity results in an accumulation of N-acetylaspartic acid"
Natural history study summarizes NAA accumulation from ASPA loss.
Reduced NAA-derived acetate and myelin lipid synthesis
Defective NAA catabolism reduces acetate availability during postnatal myelination and compromises synthesis of myelin-associated lipids.
oligodendrocyte link
lipid biosynthetic process link ↓ DECREASED central nervous system myelination link ↓ DECREASED
Downstream
Oligodendrocyte maturation and myelination defect Defective lipid supply contributes to abnormal oligodendrocyte maturation and myelination.
Show evidence (1 reference)
PMID:15784740 SUPPORT Model Organism
"myelin lipid synthesis is significantly compromised in CD"
Mouse and human white-matter lipid data support impaired myelin lipid synthesis.
Oligodendrocyte maturation and myelination defect
ASPA deficiency alters oligodendrocyte maturation, myelin gene/protein expression, histone acetylation, chromatin compaction, and myelin formation during early postnatal development.
oligodendrocyte link
central nervous system myelination link ↓ DECREASED
Downstream
Spongiform white-matter vacuolation Myelination defects and glial stress contribute to spongiform leukodystrophy.
Global developmental delay White-matter dysfunction disrupts early neurodevelopmental progress.
Hypotonia Early white-matter disease contributes to impaired motor control and hypotonia.
Show evidence (2 references)
PMID:20637282 SUPPORT Model Organism
"ASPA deficiency affects oligodendrocyte maturation and myelination"
Mouse study directly supports oligodendrocyte maturation and myelination defects.
PMID:22617649 SUPPORT Model Organism
"markers of oxidative stress preceding oligodendrocyte loss and dysmyelination"
Model study supports metabolic stress before oligodendrocyte loss and dysmyelination.
Spongiform white-matter vacuolation
Canavan disease causes dysmyelination, vacuolation, astrogliosis, and spongiform white-matter degeneration, the tissue pathology that underlies macrocephaly and progressive neurologic impairment.
oligodendrocyte link astrocyte link
Downstream
Macrocephaly Diffuse white-matter disease contributes to progressive head enlargement.
Visual impairment CNS white-matter and visual pathway involvement contribute to visual impairment.
Hypertonia Progressive white-matter disease contributes to later spasticity and hypertonia.
Seizure Progressive brain involvement contributes to epilepsy over time.
Visual pathway and ocular involvement White-matter disease affecting visual pathways contributes to visual and ocular manifestations.
Feeding and aspiration vulnerability Severe neurologic and white-matter disease contributes to impaired feeding, swallowing safety, and reflux risk.
EEG abnormality Progressive structural brain disease is linked to abnormal neurophysiology and seizures.
Flexion contracture Progressive tone abnormality and reduced mobility increase risk for contractures.
Hearing impairment Orphanet lists hearing impairment among Canavan phenotypes; the mechanistic link is uncertain.
Show evidence (2 references)
PMID:29456021 SUPPORT Model Organism
"brain dysmyelination, vacuolation, and astrogliosis"
Aspa-deficient mouse model supports spongiform leukodystrophy pathology.
PMID:20637282 SUPPORT Model Organism
"degeneration of the white matter, demyelination"
Study links Canavan disease to white-matter degeneration and demyelination.
Visual pathway and ocular involvement
Canavan white-matter disease can affect visual pathways, while structured disease records also report ocular findings. This branch connects the leukodystrophy mechanism to impaired visual tracking, blindness, optic atrophy, abnormal visual evoked potentials, nystagmus, and retinal pigmentation findings.
Downstream
Visual impairment White-matter involvement of visual pathways produces impaired visual function.
Blindness Severe visual pathway and ocular involvement can manifest as blindness.
Optic atrophy Ocular involvement includes optic atrophy in structured disease records.
Abnormality of visual evoked potentials Visual pathway disease can produce abnormal visual evoked potentials.
Nystagmus Early abnormal eye movements, including nystagmus, occur in Canavan disease.
Abnormal retinal pigmentation Structured disease records include retinal pigmentation abnormalities among ocular findings.
Show evidence (2 references)
PMID:34011350 SUPPORT Human Clinical
"visual impairment is more commonly caused by white matter disease affecting the visual pathways."
Natural history authors connect visual impairment in Canavan disease to white-matter visual pathway disease.
ORPHA:141 SUPPORT Other
"HP:0000648 | Optic atrophy | Very frequent"
Orphanet supports ocular involvement by listing optic atrophy as very frequent.
Feeding and aspiration vulnerability
Severe Canavan neurologic impairment commonly affects feeding, nutrition, and oral intake safety. Feeding therapy is recommended to maintain weight gain and reduce aspiration risk, and natural history scoring treats aspiration, inadequate weight gain, or tube feeding as feeding-severity markers.
Downstream
Feeding difficulties in infancy Neurologic feeding impairment manifests as early feeding difficulty.
Gastroesophageal reflux Feeding and swallowing impairment can coexist with reflux in severe neurologic disease.
Show evidence (2 references)
PMID:20301412 SUPPORT Other
"feeding therapy (to assure adequate nutrition and weight gain, minimize risk of"
GeneReviews supports feeding and aspiration-risk management as part of Canavan care.
PMID:34011350 SUPPORT Human Clinical
"Feeding: Score 1 if oral feeding is possible but aspiration occurs and/or weight gain is insufficient"
Natural history severity scoring includes aspiration, poor weight gain, and tube feeding as feeding manifestations.
Neuronal loss and cortical thinning
Aspartoacylase-deficient model data show cerebral cortical and cerebellar neuron depletion and progressive cortical thinning, suggesting that excess NAA and leukodystrophy are linked to neuronal injury as well as myelin pathology.
neuron link
Downstream
Cognitive impairment Neuronal and cortical injury contributes to cognitive impairment.
Reduced consciousness Severe progressive brain disease contributes to impaired alertness.
Developmental regression Progressive neuronal and white-matter injury leads to loss of acquired skills.
Show evidence (1 reference)
PMID:28077719 SUPPORT Model Organism
"cerebral cortical and cerebellar neurons are decreased"
Model study supports neuronal loss downstream of ASPA deficiency.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Canavan disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

19
Digestive 2
Gastroesophageal reflux Frequent (79-30%) Gastroesophageal reflux (HP:0002020)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0002020 | Gastroesophageal reflux | Frequent"
Orphanet reports gastroesophageal reflux as frequent.
Feeding difficulties in infancy Very frequent (99-80%) Feeding difficulties in infancy (HP:0008872)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0008872 | Feeding difficulties in infancy | Very frequent"
Orphanet reports feeding difficulties in infancy as very frequent.
Ear 1
Hearing impairment Frequent (79-30%) Hearing impairment (HP:0000365)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0000365 | Hearing impairment | Frequent"
Orphanet reports hearing impairment as frequent.
Eye 5
Visual impairment Frequent (79-30%) Visual impairment (HP:0000505)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0000505 | Visual impairment | Frequent"
Orphanet reports visual impairment as frequent.
Blindness Frequent (79-30%) Blindness (HP:0000618)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0000618 | Blindness | Frequent"
Orphanet reports blindness as frequent.
Optic atrophy Very frequent (99-80%) Optic atrophy (HP:0000648)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0000648 | Optic atrophy | Very frequent"
Orphanet reports optic atrophy as very frequent.
Nystagmus Frequent (79-30%) Nystagmus (HP:0000639)
Show evidence (1 reference)
PMID:34011350 SUPPORT Human Clinical
"abnormal eye movements (12/23)"
Natural history cohort reports abnormal eye movements in 12 of 23 patients at onset.
Abnormal retinal pigmentation Occasional (29-5%) Abnormal retinal pigmentation (HP:0007703)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0007703 | Abnormality of retinal pigmentation | Occasional"
Orphanet reports abnormal retinal pigmentation as occasional.
Head and Neck 1
Macrocephaly Frequent (79-30%) Macrocephaly (HP:0000256)
Show evidence (2 references)
ORPHA:141 SUPPORT Other
"HP:0000256 | Macrocephaly | Frequent"
Orphanet reports macrocephaly as frequent.
PMID:34011350 SUPPORT Human Clinical
"Macrocephaly became apparent between 4 and 18 months of age."
Natural history cohort supports progressive macrocephaly in infancy.
Musculoskeletal 3
Hypotonia Frequent (79-30%) Hypotonia (HP:0001252)
Show evidence (2 references)
ORPHA:141 SUPPORT Other
"HP:0001252 | Hypotonia | Frequent"
Orphanet reports hypotonia as frequent.
PMID:20301412 SUPPORT Other
"neurodevelopmental delays, macrocephaly, and tone abnormalities"
GeneReviews identifies tone abnormalities as a core disease feature.
Hypertonia Frequent (79-30%) Hypertonia (HP:0001276)
Show evidence (2 references)
ORPHA:141 SUPPORT Other
"HP:0001276 | Hypertonia | Frequent"
Orphanet reports hypertonia as frequent.
PMID:20301412 SUPPORT Other
"neurodevelopmental delays, macrocephaly, and tone abnormalities"
GeneReviews supports abnormal tone as a core clinical feature.
Flexion contracture Occasional (29-5%) Flexion contracture (HP:0001371)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0001371 | Flexion contracture | Occasional"
Orphanet reports flexion contracture as occasional.
Nervous System 5
Seizure Occasional (29-5%) Seizure (HP:0001250)
Show evidence (2 references)
ORPHA:141 SUPPORT Other
"HP:0001250 | Seizure | Occasional"
Orphanet reports seizure as occasional.
PMID:34011350 SUPPORT Human Clinical
"Seizure frequency was highest towards the end of the first decade."
Natural history cohort supports increasing seizure burden over time.
Global developmental delay Very frequent (99-80%) Global developmental delay (HP:0001263)
Show evidence (2 references)
ORPHA:141 SUPPORT Other
"HP:0001263 | Global developmental delay | Very frequent"
Orphanet reports global developmental delay as very frequent.
PMID:34011350 SUPPORT Human Clinical
"Psychomotor development of patients was limited"
Natural history cohort supports severe psychomotor developmental limitation.
EEG abnormality Very frequent (99-80%) EEG abnormality (HP:0002353)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0002353 | EEG abnormality | Very frequent"
Orphanet reports EEG abnormality as very frequent.
Developmental regression Occasional (29-5%) Developmental regression (HP:0002376)
Show evidence (2 references)
ORPHA:141 SUPPORT Other
"HP:0002376 | Developmental regression | Occasional"
Orphanet reports developmental regression as occasional.
PMID:20301412 SUPPORT Other
"followed by neurodegeneration and developmental regression"
GeneReviews identifies regression as part of typical disease course.
Cognitive impairment Very frequent (99-80%) Cognitive impairment (HP:0100543)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0100543 | Cognitive impairment | Very frequent"
Orphanet reports cognitive impairment as very frequent.
Other 2
Abnormality of visual evoked potentials Frequent (79-30%) Abnormality of visual evoked potentials (HP:0000649)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0000649 | Abnormality of visual evoked potentials | Frequent"
Orphanet reports abnormal visual evoked potentials as frequent.
Reduced consciousness Very frequent (99-80%) Reduced consciousness (HP:0004372)
Show evidence (1 reference)
ORPHA:141 SUPPORT Other
"HP:0004372 | Reduced consciousness/confusion | Very frequent"
Orphanet reports reduced consciousness/confusion as very frequent.
🧬

Genetic Associations

1
ASPA (Causal loss-of-function variant)
Show evidence (3 references)
PMID:20301412 SUPPORT Other
"biallelic ASPA pathogenic variants identified by molecular genetic testing"
GeneReviews identifies biallelic ASPA pathogenic variants as diagnostic.
PMID:28101991 SUPPORT Human Clinical
"We have detected a correlation between clinical presentation, enzyme activity, and genotype"
Patient variant study supports genotype-enzyme-phenotype correlation.
CGGV:assertion_66306eff-659f-4508-a41b-1820e47e0e1d-2020-10-08T161701.633Z SUPPORT Other
"ASPA | HGNC:756 | Canavan disease | MONDO:0010079 | AR | Definitive"
ClinGen classifies the ASPA-Canavan disease gene-disease relationship as definitive with autosomal recessive inheritance.
💊

Treatments

3
Multidisciplinary supportive care
Action: supportive care MAXO:0000950
Standard care is supportive and multidisciplinary, including neurology for seizures and spasticity, rehabilitation therapies for mobility and contracture prevention, feeding therapy and nutritional support, respiratory monitoring, educational supports, and palliative or respite care as needed.
Target Phenotypes: Seizure ↗ Hypertonia ↗ Feeding difficulties in infancy ↗
Show evidence (1 reference)
PMID:20301412 SUPPORT Other
"Multidisciplinary care by specialists in neurology"
GeneReviews supports multidisciplinary supportive management.
ASPA gene replacement therapy
Action: gene therapy MAXO:0001001
AAV-mediated ASPA gene replacement is an investigational disease-modifying strategy intended to restore aspartoacylase expression. Early human reports and active trials support biological plausibility, but it remains a developing therapy rather than established standard care.
Mechanism Target:
RESTORES Aspartoacylase enzyme deficiency — AAV-ASPA strategies provide a functional ASPA transgene to restore enzyme activity.
Show evidence (1 reference)
PMID:37601414 SUPPORT Human Clinical
"Gene replacement therapy is a rational therapeutic strategy"
Expanded-access case report supports ASPA gene replacement rationale.
Show evidence (2 references)
PMID:37601414 SUPPORT Human Clinical
"NAA level was reduced at 3 months"
Single-patient report supports biochemical effect after AAV9-CB6-ASPA therapy.
PMID:37755460 PARTIAL Other
"gene therapy is emerging as a potential treatment avenue"
Leukodystrophy trials review supports active therapeutic development for this disease class.
NAT8L/NAA-lowering strategy
Lowering NAA synthesis through NAT8L suppression is a preclinical strategy that targets the toxic upstream substrate burden rather than replacing ASPA. It is included as a model-supported investigational mechanism, not as an established human treatment.
Mechanism Target:
INHIBITS NAA accumulation in CNS and body fluids — Reducing neuronal NAA synthesis lowers substrate accumulation upstream of spongiform leukodystrophy.
Show evidence (1 reference)
PMID:29456021 SUPPORT Model Organism
"suppresses development of spongiform leukodystrophy"
AAV-shRNA Nat8l knockdown lowered brain NAA and suppressed leukodystrophy in mice.
Show evidence (1 reference)
PMID:28077719 SUPPORT Model Organism
"prevents neuron loss and cerebral cortical atrophy"
Model study supports NAA synthesis suppression as a neuroprotective strategy.
🔬

Biochemical Markers

2
Elevated urinary N-acetylaspartic acid (INCREASED)
Context: Elevated urinary NAA is the classic biochemical diagnostic marker of Canavan disease and reports systemic accumulation caused by ASPA deficiency.
Pathograph Readouts
Readout Of NAA accumulation in CNS and body fluids Positive Diagnostic
Higher urinary NAA reflects the NAA accumulation caused by impaired ASPA-mediated catabolism.
Show evidence (1 reference)
PMID:28101991 SUPPORT Human Clinical
"Elevation of NAA levels in urine is the biochemical hallmark of CD."
Patient variant study identifies urinary NAA elevation as the biochemical hallmark.
Show evidence (2 references)
PMID:20301412 SUPPORT Other
"elevated N-acetylaspartic acid (NAA) in urine"
GeneReviews supports elevated urinary NAA as biochemical diagnostic evidence.
PMID:28101991 SUPPORT Human Clinical
"Elevation of NAA levels in urine is the biochemical hallmark of CD."
Patient variant study supports urinary NAA as the biochemical hallmark.
Elevated brain NAA by proton MR spectroscopy (INCREASED)
Context: Proton MR spectroscopy can detect elevated NAA in the brain, providing a CNS biochemical readout of the same substrate accumulation.
Pathograph Readouts
Readout Of NAA accumulation in CNS and body fluids Positive Diagnostic
Elevated brain NAA by MRS reports CNS NAA accumulation downstream of ASPA deficiency.
Show evidence (1 reference)
PMID:34011350 SUPPORT Human Clinical
"CD is diagnosed by detection of elevated NAA in urine or blood or in brain by proton MR spectroscopy"
Natural history study supports MRS-detected brain NAA as a diagnostic readout.
Show evidence (2 references)
PMID:20301412 SUPPORT Other
"in the brain by proton magnetic resonance spectroscopy"
GeneReviews supports proton MRS detection of brain NAA.
PMID:34011350 SUPPORT Human Clinical
"CD is diagnosed by detection of elevated NAA in urine or blood or in brain by proton MR spectroscopy"
Natural history study supports elevated NAA in brain by proton MR spectroscopy.
🔬

Clinical Trials

2
NCT04998396 PHASE_I RECRUITING
Phase 1/2 open-label study of BBP-812, an investigational systemic AAV9-based ASPA gene therapy, in pediatric participants with Canavan disease.
Target Phenotypes: Global developmental delay ↗ Hypotonia ↗
Show evidence (1 reference)
clinicaltrials:NCT04998396 SUPPORT Human Clinical
"The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease."
ClinicalTrials.gov records an active pediatric AAV9-ASPA gene-therapy trial for Canavan disease.
NCT04833907 PHASE_I ENROLLING_BY_INVITATION
Phase 1/2 open-label sequential-cohort study of a single intracranial dose of AVASPA/rAAV-Olig001-ASPA gene therapy for children with typical Canavan disease.
Target Phenotypes: Hypomyelination ↗ Seizure ↗
Show evidence (1 reference)
clinicaltrials:NCT04833907 SUPPORT Human Clinical
"The latest generation AAV viral vector (rAAV-Olig001-ASPA) will be administered to patients using neurosurgical procedure which involves direct administration of gene therapy to affected regions of the brain."
ClinicalTrials.gov records an intracranial oligodendrocyte-targeted ASPA gene-therapy trial for typical Canavan disease.
{ }

Source YAML

click to show 
name: Canavan disease
category: Mendelian
creation_date: '2026-05-03T17:22:49Z'
updated_date: '2026-05-19T11:28:40Z'
synonyms:
- ACY2 deficiency
- Aminoacylase 2 deficiency
- Aspartoacylase deficiency
- Spongy degeneration of the brain
description: >
  Canavan disease is an autosomal recessive leukodystrophy caused by biallelic
  pathogenic variants in ASPA, encoding aspartoacylase. Aspartoacylase
  deficiency impairs hydrolysis of N-acetyl-L-aspartate to acetate and
  aspartate, leading to NAA accumulation in the central nervous system and body
  fluids, spongiform white-matter degeneration, dysmyelination, severe
  infantile-onset neurodevelopmental impairment, macrocephaly, tone
  abnormalities, visual impairment, feeding difficulty, and progressive
  neurologic disability.
disease_term:
  preferred_term: Canavan disease
  term:
    id: MONDO:0010079
    label: Canavan disease
parents:
- Leukodystrophy
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010079
      label: Canavan disease
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:141
    mapping_justification: >
      Orphanet ORPHA:141 lists MONDO:0010079 as an exact cross-reference for
      Canavan disease.
external_assertions:
- name: Orphanet Canavan disease record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:141
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141
  description: >
    Orphanet's ORPHA:141 structured record for Canavan disease includes the
    exact MONDO cross-reference, definition, autosomal recessive inheritance,
    epidemiology, OMIM cross-reference, and HPO phenotype annotations used in
    this entry.
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0010079 | Exact"
    explanation: Orphanet maps ORPHA:141 to the MONDO identifier used by this entry.
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:271900 | Exact"
    explanation: Orphanet lists OMIM:271900 as an exact external cross-reference.
definitions:
- name: Orphanet Canavan disease definition
  definition_type: OTHER
  description: >
    A neurodegenerative disorder ranging from severe leukodystrophy with
    macrocephaly and severe developmental delay to very rare mild/juvenile
    disease with milder developmental delay.
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "neurodegenerative disorder; its spectrum varies between severe forms with leukodystrophy"
    explanation: Orphanet defines Canavan disease as a spectrum neurodegenerative leukodystrophy.
inheritance:
- name: Autosomal recessive inheritance
  description: Canavan disease is inherited in an autosomal recessive pattern.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for Canavan disease.
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Canavan disease is inherited in an autosomal recessive manner."
    explanation: GeneReviews confirms autosomal recessive inheritance.
prevalence:
- population: Worldwide
  percentage: Unknown
  notes: >
    Orphanet records worldwide point prevalence as unknown and worldwide
    prevalence at birth in the 1-9 per 100,000 band.
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Unknown | Worldwide | Point prevalence | ORPHANET"
    explanation: Orphanet records worldwide point prevalence as unknown.
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Prevalence at birth"
    explanation: Orphanet records a worldwide prevalence-at-birth band.
progression:
- phase: Typical infantile Canavan disease
  age_range: Infancy
  notes: >
    Typical disease presents after early normal appearance, with hypotonia,
    head lag, macrocephaly, neurodevelopmental impairment by three to five
    months, followed by neurodegeneration, developmental regression, increasing
    feeding problems, seizures, and reduced survival.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "neurodevelopmental impairment evident by ages three to five months"
    explanation: GeneReviews describes the typical early-infantile onset window.
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Onset of symptoms was between 0 and 6 months."
    explanation: Natural history cohort supports early infantile symptom onset.
- phase: Atypical milder Canavan disease
  age_range: Infancy to childhood or adolescence
  notes: >
    Atypical disease is less common and may present later with milder
    developmental delay, variable macrocephaly, visual impairment or nystagmus,
    ataxia or coordination difficulty, and possible later regression.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "atypical Canavan disease is more variable"
    explanation: GeneReviews describes atypical Canavan disease as a variable milder spectrum.
  - reference: PMID:28101991
    reference_title: "Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mutations found in the mild patients corresponded to the variants with the highest residual enzyme activities"
    explanation: Residual ASPA activity supports the milder phenotypic spectrum.
genetic:
- name: ASPA
  association: Causal loss-of-function variant
  gene_term:
    preferred_term: ASPA
    term:
      id: hgnc:756
      label: ASPA
  notes: >
    Canavan disease is caused by biallelic pathogenic variants in ASPA. Severe
    alleles generally abolish aspartoacylase activity, while some missense
    variants retain residual activity and can produce atypical milder disease.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "biallelic ASPA pathogenic variants identified by molecular genetic testing"
    explanation: GeneReviews identifies biallelic ASPA pathogenic variants as diagnostic.
  - reference: PMID:28101991
    reference_title: "Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have detected a correlation between clinical presentation, enzyme activity, and genotype"
    explanation: Patient variant study supports genotype-enzyme-phenotype correlation.
  - reference: CGGV:assertion_66306eff-659f-4508-a41b-1820e47e0e1d-2020-10-08T161701.633Z
    reference_title: "ASPA / Canavan disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ASPA | HGNC:756 | Canavan disease | MONDO:0010079 | AR | Definitive"
    explanation: ClinGen classifies the ASPA-Canavan disease gene-disease relationship as definitive with autosomal recessive inheritance.
pathophysiology:
- name: ASPA variant protein destabilization
  description: >
    Many disease-linked ASPA missense variants destabilize the aspartoacylase
    protein, promoting misfolding and proteasomal degradation and thereby
    reducing active enzyme abundance.
  genes:
  - preferred_term: ASPA
    term:
      id: hgnc:756
      label: ASPA
  biological_processes:
  - preferred_term: protein folding
    modifier: ABNORMAL
    term:
      id: GO:0006457
      label: protein folding
  evidence:
  - reference: PMID:38582917
    reference_title: "Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "most disease linked ASPA gene variants lead to a structural destabilization"
    explanation: Recent review supports ASPA protein destabilization as a common mechanism.
  downstream:
  - target: Aspartoacylase enzyme deficiency
    description: Destabilized ASPA variants reduce functional aspartoacylase activity.
    causal_link_type: DIRECT
- name: Aspartoacylase enzyme deficiency
  description: >
    Loss of ASPA activity impairs the cytosolic/oligodendroglial hydrolysis of
    N-acetyl-L-aspartate to acetate and aspartate, initiating the core
    biochemical disease cascade.
  genes:
  - preferred_term: ASPA
    term:
      id: hgnc:756
      label: ASPA
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  cellular_components:
  - preferred_term: cytosol
    term:
      id: GO:0005829
      label: cytosol
  biological_processes:
  - preferred_term: N-acetylaspartate/aspartate metabolism
    modifier: ABNORMAL
    term:
      id: GO:0006531
      label: aspartate metabolic process
  molecular_functions:
  - preferred_term: aspartoacylase activity
    modifier: DECREASED
    term:
      id: GO:0016811
      label: hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
  evidence:
  - reference: PMID:38582917
    reference_title: "Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "deficiency of the cytosolic aspartoacylase (ASPA) enzyme"
    explanation: Mechanistic review directly identifies aspartoacylase deficiency.
  - reference: PMID:15784740
    reference_title: "Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "ASPA acts to hydrolyze N-acetylaspartate (NAA) into l-aspartate and acetate"
    explanation: Mouse model study describes the enzymatic reaction blocked in Canavan disease.
  downstream:
  - target: NAA accumulation in CNS and body fluids
    description: Failure to catabolize NAA causes substrate accumulation.
    causal_link_type: DIRECT
  - target: Reduced NAA-derived acetate and myelin lipid synthesis
    description: Loss of NAA hydrolysis limits acetate availability for myelin lipid synthesis.
    causal_link_type: DIRECT
- name: NAA accumulation in CNS and body fluids
  description: >
    Aspartoacylase deficiency causes N-acetyl-L-aspartate to accumulate in the
    brain, urine, blood, cerebrospinal fluid, and other body fluids. Elevated
    urinary NAA and brain NAA by proton magnetic resonance spectroscopy are key
    diagnostic biochemical markers.
  chemical_entities:
  - preferred_term: N-acetyl-L-aspartic acid
    modifier: INCREASED
    term:
      id: CHEBI:21547
      label: N-acetyl-L-aspartic acid
  evidence:
  - reference: PMID:8412017
    reference_title: "Canavan disease: biochemical and molecular studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deficiency of the enzyme aspartoacylase and the accumulation of N-acetylaspartic acid"
    explanation: Biochemical study supports the enzyme-substrate defect.
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "loss of ASPA activity results in an accumulation of N-acetylaspartic acid"
    explanation: Natural history study summarizes NAA accumulation from ASPA loss.
  downstream:
  - target: Spongiform white-matter vacuolation
    description: High CNS NAA contributes to intramyelinic and white-matter vacuolation.
    causal_link_type: DIRECT
  - target: Neuronal loss and cortical thinning
    description: Model data link excess NAA to neuronal loss and cortical atrophy.
    causal_link_type: DIRECT
  - target: Elevated urinary N-acetylaspartic acid
    description: Elevated urinary NAA is a diagnostic readout of systemic NAA accumulation.
    causal_link_type: DIRECT
  - target: Elevated brain NAA by proton MR spectroscopy
    description: Elevated brain NAA by MRS is a diagnostic readout of CNS NAA accumulation.
    causal_link_type: DIRECT
- name: Reduced NAA-derived acetate and myelin lipid synthesis
  description: >
    Defective NAA catabolism reduces acetate availability during postnatal
    myelination and compromises synthesis of myelin-associated lipids.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: lipid biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0008610
      label: lipid biosynthetic process
  - preferred_term: central nervous system myelination
    modifier: DECREASED
    term:
      id: GO:0022010
      label: central nervous system myelination
  chemical_entities:
  - preferred_term: acetate
    modifier: DECREASED
    term:
      id: CHEBI:30089
      label: acetate
  evidence:
  - reference: PMID:15784740
    reference_title: "Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "myelin lipid synthesis is significantly compromised in CD"
    explanation: Mouse and human white-matter lipid data support impaired myelin lipid synthesis.
  downstream:
  - target: Oligodendrocyte maturation and myelination defect
    description: Defective lipid supply contributes to abnormal oligodendrocyte maturation and myelination.
    causal_link_type: DIRECT
- name: Oligodendrocyte maturation and myelination defect
  description: >
    ASPA deficiency alters oligodendrocyte maturation, myelin gene/protein
    expression, histone acetylation, chromatin compaction, and myelin formation
    during early postnatal development.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: central nervous system myelination
    modifier: DECREASED
    term:
      id: GO:0022010
      label: central nervous system myelination
  evidence:
  - reference: PMID:20637282
    reference_title: "Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "ASPA deficiency affects oligodendrocyte maturation and myelination"
    explanation: Mouse study directly supports oligodendrocyte maturation and myelination defects.
  - reference: PMID:22617649
    reference_title: "Aspartoacylase supports oxidative energy metabolism during myelination."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "markers of oxidative stress preceding oligodendrocyte loss and dysmyelination"
    explanation: Model study supports metabolic stress before oligodendrocyte loss and dysmyelination.
  downstream:
  - target: Spongiform white-matter vacuolation
    description: Myelination defects and glial stress contribute to spongiform leukodystrophy.
    causal_link_type: DIRECT
  - target: Global developmental delay
    description: White-matter dysfunction disrupts early neurodevelopmental progress.
    causal_link_type: DIRECT
  - target: Hypotonia
    description: Early white-matter disease contributes to impaired motor control and hypotonia.
    causal_link_type: DIRECT
- name: Spongiform white-matter vacuolation
  description: >
    Canavan disease causes dysmyelination, vacuolation, astrogliosis, and
    spongiform white-matter degeneration, the tissue pathology that underlies
    macrocephaly and progressive neurologic impairment.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  evidence:
  - reference: PMID:29456021
    reference_title: "Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "brain dysmyelination, vacuolation, and astrogliosis"
    explanation: Aspa-deficient mouse model supports spongiform leukodystrophy pathology.
  - reference: PMID:20637282
    reference_title: "Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "degeneration of the white matter, demyelination"
    explanation: Study links Canavan disease to white-matter degeneration and demyelination.
  downstream:
  - target: Macrocephaly
    description: Diffuse white-matter disease contributes to progressive head enlargement.
    causal_link_type: DIRECT
  - target: Visual impairment
    description: CNS white-matter and visual pathway involvement contribute to visual impairment.
    causal_link_type: DIRECT
  - target: Hypertonia
    description: Progressive white-matter disease contributes to later spasticity and hypertonia.
    causal_link_type: DIRECT
  - target: Seizure
    description: Progressive brain involvement contributes to epilepsy over time.
    causal_link_type: DIRECT
  - target: Visual pathway and ocular involvement
    description: White-matter disease affecting visual pathways contributes to visual and ocular manifestations.
    causal_link_type: DIRECT
  - target: Feeding and aspiration vulnerability
    description: Severe neurologic and white-matter disease contributes to impaired feeding, swallowing safety, and reflux risk.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: EEG abnormality
    description: Progressive structural brain disease is linked to abnormal neurophysiology and seizures.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:141
      reference_title: "Canavan disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002353 | EEG abnormality | Very frequent"
      explanation: Orphanet reports EEG abnormality as a very frequent Canavan disease phenotype.
  - target: Flexion contracture
    description: Progressive tone abnormality and reduced mobility increase risk for contractures.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301412
      reference_title: "Canavan Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "(to minimize contractures, optimize abilities and seating posture)"
      explanation: GeneReviews recommends rehabilitation management to minimize contractures in Canavan disease.
  - target: Hearing impairment
    description: Orphanet lists hearing impairment among Canavan phenotypes; the mechanistic link is uncertain.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:141
      reference_title: "Canavan disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000365 | Hearing impairment | Frequent"
      explanation: Orphanet reports hearing impairment as a frequent phenotype.
    - reference: PMID:34011350
      reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
      supports: REFUTE
      evidence_source: HUMAN_CLINICAL
      snippet: "All CD patients were reported by caregivers and medical records to be able to hear at birth and throughout the course of disease."
      explanation: A 23-patient natural history cohort found preserved hearing, so the mechanism edge is retained only as an uncertain Orphanet-reported association.
- name: Visual pathway and ocular involvement
  description: >
    Canavan white-matter disease can affect visual pathways, while structured
    disease records also report ocular findings. This branch connects the
    leukodystrophy mechanism to impaired visual tracking, blindness, optic
    atrophy, abnormal visual evoked potentials, nystagmus, and retinal
    pigmentation findings.
  evidence:
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "visual impairment is more commonly caused by white matter disease affecting the visual pathways."
    explanation: Natural history authors connect visual impairment in Canavan disease to white-matter visual pathway disease.
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000648 | Optic atrophy | Very frequent"
    explanation: Orphanet supports ocular involvement by listing optic atrophy as very frequent.
  downstream:
  - target: Visual impairment
    description: White-matter involvement of visual pathways produces impaired visual function.
    causal_link_type: DIRECT
  - target: Blindness
    description: Severe visual pathway and ocular involvement can manifest as blindness.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Optic atrophy
    description: Ocular involvement includes optic atrophy in structured disease records.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Abnormality of visual evoked potentials
    description: Visual pathway disease can produce abnormal visual evoked potentials.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Nystagmus
    description: Early abnormal eye movements, including nystagmus, occur in Canavan disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Abnormal retinal pigmentation
    description: Structured disease records include retinal pigmentation abnormalities among ocular findings.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Feeding and aspiration vulnerability
  description: >
    Severe Canavan neurologic impairment commonly affects feeding, nutrition,
    and oral intake safety. Feeding therapy is recommended to maintain weight
    gain and reduce aspiration risk, and natural history scoring treats
    aspiration, inadequate weight gain, or tube feeding as feeding-severity
    markers.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "feeding therapy (to assure adequate nutrition and weight gain, minimize risk of"
    explanation: GeneReviews supports feeding and aspiration-risk management as part of Canavan care.
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Feeding: Score 1 if oral feeding is possible but aspiration occurs and/or weight gain is insufficient"
    explanation: Natural history severity scoring includes aspiration, poor weight gain, and tube feeding as feeding manifestations.
  downstream:
  - target: Feeding difficulties in infancy
    description: Neurologic feeding impairment manifests as early feeding difficulty.
    causal_link_type: DIRECT
  - target: Gastroesophageal reflux
    description: Feeding and swallowing impairment can coexist with reflux in severe neurologic disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Neuronal loss and cortical thinning
  description: >
    Aspartoacylase-deficient model data show cerebral cortical and cerebellar
    neuron depletion and progressive cortical thinning, suggesting that excess
    NAA and leukodystrophy are linked to neuronal injury as well as myelin
    pathology.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:28077719
    reference_title: "Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "cerebral cortical and cerebellar neurons are decreased"
    explanation: Model study supports neuronal loss downstream of ASPA deficiency.
  downstream:
  - target: Cognitive impairment
    description: Neuronal and cortical injury contributes to cognitive impairment.
    causal_link_type: DIRECT
  - target: Reduced consciousness
    description: Severe progressive brain disease contributes to impaired alertness.
    causal_link_type: DIRECT
  - target: Developmental regression
    description: Progressive neuronal and white-matter injury leads to loss of acquired skills.
    causal_link_type: DIRECT
phenotypes:
- name: Macrocephaly
  category: Neurologic
  description: Macrocephaly is a frequent and often progressive finding in typical Canavan disease.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  frequency: Frequent (79-30%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000256 | Macrocephaly | Frequent"
    explanation: Orphanet reports macrocephaly as frequent.
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Macrocephaly became apparent between 4 and 18 months of age."
    explanation: Natural history cohort supports progressive macrocephaly in infancy.
- name: Hearing impairment
  category: Neurologic
  description: Hearing impairment is listed by Orphanet among frequent Canavan disease phenotypes.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  frequency: Frequent (79-30%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000365 | Hearing impairment | Frequent"
    explanation: Orphanet reports hearing impairment as frequent.
- name: Visual impairment
  category: Neurologic
  description: Visual impairment is frequent and may include poor visual tracking, nystagmus, and cerebral visual impairment.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  frequency: Frequent (79-30%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000505 | Visual impairment | Frequent"
    explanation: Orphanet reports visual impairment as frequent.
- name: Blindness
  category: Neurologic
  description: Blindness is a frequent Orphanet phenotype for Canavan disease.
  phenotype_term:
    preferred_term: Blindness
    term:
      id: HP:0000618
      label: Blindness
  frequency: Frequent (79-30%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000618 | Blindness | Frequent"
    explanation: Orphanet reports blindness as frequent.
- name: Optic atrophy
  category: Ophthalmologic
  description: Optic atrophy is a very frequent Orphanet phenotype for Canavan disease.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  frequency: Very frequent (99-80%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000648 | Optic atrophy | Very frequent"
    explanation: Orphanet reports optic atrophy as very frequent.
- name: Abnormality of visual evoked potentials
  category: Neurophysiologic
  description: Abnormal visual evoked potentials are a frequent neurophysiologic manifestation.
  phenotype_term:
    preferred_term: Abnormality of visual evoked potentials
    term:
      id: HP:0000649
      label: Abnormality of visual evoked potentials
  frequency: Frequent (79-30%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000649 | Abnormality of visual evoked potentials | Frequent"
    explanation: Orphanet reports abnormal visual evoked potentials as frequent.
- name: Nystagmus
  category: Ophthalmologic
  description: Nystagmus and other abnormal eye movements are common early manifestations.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  frequency: Frequent (79-30%)
  evidence:
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormal eye movements (12/23)"
    explanation: Natural history cohort reports abnormal eye movements in 12 of 23 patients at onset.
- name: Seizure
  category: Neurologic
  description: Seizures are an occasional Orphanet phenotype and become more common over time in natural history data.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: Occasional (29-5%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Occasional"
    explanation: Orphanet reports seizure as occasional.
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizure frequency was highest towards the end of the first decade."
    explanation: Natural history cohort supports increasing seizure burden over time.
- name: Hypotonia
  category: Neurologic
  description: Hypotonia is a frequent early motor-tone abnormality in typical Canavan disease.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  frequency: Frequent (79-30%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001252 | Hypotonia | Frequent"
    explanation: Orphanet reports hypotonia as frequent.
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "neurodevelopmental delays, macrocephaly, and tone abnormalities"
    explanation: GeneReviews identifies tone abnormalities as a core disease feature.
- name: Global developmental delay
  category: Neurodevelopmental
  description: Global developmental delay is a very frequent core manifestation.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: Very frequent (99-80%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001263 | Global developmental delay | Very frequent"
    explanation: Orphanet reports global developmental delay as very frequent.
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Psychomotor development of patients was limited"
    explanation: Natural history cohort supports severe psychomotor developmental limitation.
- name: Hypertonia
  category: Neurologic
  description: Hypertonia is frequent and often develops as hypotonia evolves into spasticity.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  frequency: Frequent (79-30%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001276 | Hypertonia | Frequent"
    explanation: Orphanet reports hypertonia as frequent.
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "neurodevelopmental delays, macrocephaly, and tone abnormalities"
    explanation: GeneReviews supports abnormal tone as a core clinical feature.
- name: Flexion contracture
  category: Musculoskeletal
  description: Flexion contractures are an occasional musculoskeletal complication of progressive motor impairment.
  phenotype_term:
    preferred_term: Flexion contracture
    term:
      id: HP:0001371
      label: Flexion contracture
  frequency: Occasional (29-5%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001371 | Flexion contracture | Occasional"
    explanation: Orphanet reports flexion contracture as occasional.
- name: Gastroesophageal reflux
  category: Gastrointestinal
  description: Gastroesophageal reflux is a frequent gastrointestinal manifestation.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  frequency: Frequent (79-30%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002020 | Gastroesophageal reflux | Frequent"
    explanation: Orphanet reports gastroesophageal reflux as frequent.
- name: EEG abnormality
  category: Neurophysiologic
  description: EEG abnormality is a very frequent neurophysiologic finding.
  phenotype_term:
    preferred_term: EEG abnormality
    term:
      id: HP:0002353
      label: EEG abnormality
  frequency: Very frequent (99-80%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002353 | EEG abnormality | Very frequent"
    explanation: Orphanet reports EEG abnormality as very frequent.
- name: Developmental regression
  category: Neurodevelopmental
  description: Developmental regression is an occasional Orphanet phenotype and follows early impairment in typical disease.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  frequency: Occasional (29-5%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002376 | Developmental regression | Occasional"
    explanation: Orphanet reports developmental regression as occasional.
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "followed by neurodegeneration and developmental regression"
    explanation: GeneReviews identifies regression as part of typical disease course.
- name: Reduced consciousness
  category: Neurologic
  description: Reduced consciousness or confusion is a very frequent severe neurologic manifestation in Orphanet.
  phenotype_term:
    preferred_term: Reduced consciousness
    term:
      id: HP:0004372
      label: Reduced consciousness
  frequency: Very frequent (99-80%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004372 | Reduced consciousness/confusion | Very frequent"
    explanation: Orphanet reports reduced consciousness/confusion as very frequent.
- name: Abnormal retinal pigmentation
  category: Ophthalmologic
  description: Abnormal retinal pigmentation is an occasional ocular phenotype.
  phenotype_term:
    preferred_term: Abnormal retinal pigmentation
    term:
      id: HP:0007703
      label: Abnormal retinal pigmentation
  frequency: Occasional (29-5%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007703 | Abnormality of retinal pigmentation | Occasional"
    explanation: Orphanet reports abnormal retinal pigmentation as occasional.
- name: Feeding difficulties in infancy
  category: Gastrointestinal
  description: Feeding difficulty in infancy is a very frequent manifestation and may worsen as swallowing deteriorates.
  phenotype_term:
    preferred_term: Feeding difficulties in infancy
    term:
      id: HP:0008872
      label: Feeding difficulties in infancy
  frequency: Very frequent (99-80%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008872 | Feeding difficulties in infancy | Very frequent"
    explanation: Orphanet reports feeding difficulties in infancy as very frequent.
- name: Cognitive impairment
  category: Neurodevelopmental
  description: Cognitive impairment is a very frequent consequence of severe neurodevelopmental disease.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  frequency: Very frequent (99-80%)
  evidence:
  - reference: ORPHA:141
    reference_title: "Canavan disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100543 | Cognitive impairment | Very frequent"
    explanation: Orphanet reports cognitive impairment as very frequent.
biochemical:
- name: Elevated urinary N-acetylaspartic acid
  presence: INCREASED
  context: >
    Elevated urinary NAA is the classic biochemical diagnostic marker of
    Canavan disease and reports systemic accumulation caused by ASPA deficiency.
  biomarker_term:
    preferred_term: N-acetyl-L-aspartic acid
    term:
      id: CHEBI:21547
      label: N-acetyl-L-aspartic acid
  readouts:
  - target: NAA accumulation in CNS and body fluids
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Higher urinary NAA reflects the NAA accumulation caused by impaired ASPA-mediated catabolism.
    evidence:
    - reference: PMID:28101991
      reference_title: "Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Elevation of NAA levels in urine is the biochemical hallmark of CD."
      explanation: Patient variant study identifies urinary NAA elevation as the biochemical hallmark.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "elevated N-acetylaspartic acid (NAA) in urine"
    explanation: GeneReviews supports elevated urinary NAA as biochemical diagnostic evidence.
  - reference: PMID:28101991
    reference_title: "Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Elevation of NAA levels in urine is the biochemical hallmark of CD."
    explanation: Patient variant study supports urinary NAA as the biochemical hallmark.
- name: Elevated brain NAA by proton MR spectroscopy
  presence: INCREASED
  context: >
    Proton MR spectroscopy can detect elevated NAA in the brain, providing a CNS
    biochemical readout of the same substrate accumulation.
  biomarker_term:
    preferred_term: N-acetyl-L-aspartic acid
    term:
      id: CHEBI:21547
      label: N-acetyl-L-aspartic acid
  readouts:
  - target: NAA accumulation in CNS and body fluids
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated brain NAA by MRS reports CNS NAA accumulation downstream of ASPA deficiency.
    evidence:
    - reference: PMID:34011350
      reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CD is diagnosed by detection of elevated NAA in urine or blood or in brain by proton MR spectroscopy"
      explanation: Natural history study supports MRS-detected brain NAA as a diagnostic readout.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in the brain by proton magnetic resonance spectroscopy"
    explanation: GeneReviews supports proton MRS detection of brain NAA.
  - reference: PMID:34011350
    reference_title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CD is diagnosed by detection of elevated NAA in urine or blood or in brain by proton MR spectroscopy"
    explanation: Natural history study supports elevated NAA in brain by proton MR spectroscopy.
diagnosis:
- name: Urinary N-acetylaspartic acid testing
  description: >
    Biochemical diagnosis can be established by detecting elevated NAA in urine,
    particularly in typical Canavan disease.
  results: Elevated urinary NAA supports Canavan disease.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "elevated N-acetylaspartic acid (NAA) in urine"
    explanation: GeneReviews supports urinary NAA testing for biochemical diagnosis.
  - reference: PMID:28101991
    reference_title: "Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Elevation of NAA levels in urine is the biochemical hallmark"
    explanation: Patient variant study supports urinary NAA as a biochemical hallmark.
- name: Brain proton magnetic resonance spectroscopy for NAA
  description: >
    Proton magnetic resonance spectroscopy can detect elevated brain NAA and
    supports diagnosis when combined with clinical and genetic findings.
  results: Elevated brain NAA supports Canavan disease.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in the brain by proton magnetic resonance spectroscopy"
    explanation: GeneReviews supports brain MRS for detecting NAA.
- name: ASPA molecular genetic testing
  description: Molecular testing confirms diagnosis by identifying biallelic pathogenic ASPA variants.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
    qualifiers:
    - predicate:
        preferred_term: has participant
        term:
          id: RO:0000057
          label: has participant
      value:
        preferred_term: ASPA
        term:
          id: hgnc:756
          label: ASPA
  results: Biallelic pathogenic ASPA variants confirm Canavan disease.
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "biallelic ASPA pathogenic variants identified by molecular genetic testing"
    explanation: GeneReviews supports ASPA molecular testing as confirmatory.
treatments:
- name: Multidisciplinary supportive care
  description: >
    Standard care is supportive and multidisciplinary, including neurology for
    seizures and spasticity, rehabilitation therapies for mobility and
    contracture prevention, feeding therapy and nutritional support, respiratory
    monitoring, educational supports, and palliative or respite care as needed.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  - preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  - preferred_term: Feeding difficulties in infancy
    term:
      id: HP:0008872
      label: Feeding difficulties in infancy
  evidence:
  - reference: PMID:20301412
    reference_title: "Canavan Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Multidisciplinary care by specialists in neurology"
    explanation: GeneReviews supports multidisciplinary supportive management.
- name: ASPA gene replacement therapy
  description: >
    AAV-mediated ASPA gene replacement is an investigational disease-modifying
    strategy intended to restore aspartoacylase expression. Early human reports
    and active trials support biological plausibility, but it remains a
    developing therapy rather than established standard care.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: Aspartoacylase enzyme deficiency
    treatment_effect: RESTORES
    description: AAV-ASPA strategies provide a functional ASPA transgene to restore enzyme activity.
    evidence:
    - reference: PMID:37601414
      reference_title: "Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Gene replacement therapy is a rational therapeutic strategy"
      explanation: Expanded-access case report supports ASPA gene replacement rationale.
  evidence:
  - reference: PMID:37601414
    reference_title: "Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NAA level was reduced at 3 months"
    explanation: Single-patient report supports biochemical effect after AAV9-CB6-ASPA therapy.
  - reference: PMID:37755460
    reference_title: "Update on leukodystrophies and developing trials."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "gene therapy is emerging as a potential treatment avenue"
    explanation: Leukodystrophy trials review supports active therapeutic development for this disease class.
- name: NAT8L/NAA-lowering strategy
  description: >
    Lowering NAA synthesis through NAT8L suppression is a preclinical strategy
    that targets the toxic upstream substrate burden rather than replacing
    ASPA. It is included as a model-supported investigational mechanism, not as
    an established human treatment.
  target_mechanisms:
  - target: NAA accumulation in CNS and body fluids
    treatment_effect: INHIBITS
    description: Reducing neuronal NAA synthesis lowers substrate accumulation upstream of spongiform leukodystrophy.
    evidence:
    - reference: PMID:29456021
      reference_title: "Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "suppresses development of spongiform leukodystrophy"
      explanation: AAV-shRNA Nat8l knockdown lowered brain NAA and suppressed leukodystrophy in mice.
  evidence:
  - reference: PMID:28077719
    reference_title: "Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "prevents neuron loss and cerebral cortical atrophy"
    explanation: Model study supports NAA synthesis suppression as a neuroprotective strategy.
clinical_trials:
- name: NCT04998396
  phase: PHASE_I
  status: RECRUITING
  description: >
    Phase 1/2 open-label study of BBP-812, an investigational systemic
    AAV9-based ASPA gene therapy, in pediatric participants with Canavan disease.
  target_phenotypes:
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  - preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: clinicaltrials:NCT04998396
    reference_title: "A Phase 1/2 Open-Label Study of the Safety and Clinical Activity of Gene Therapy for Canavan Disease Through Administration of an Adeno-Associated Virus (AAV) Serotype 9-Based Recombinant Vector Encoding the Human ASPA Gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease."
    explanation: ClinicalTrials.gov records an active pediatric AAV9-ASPA gene-therapy trial for Canavan disease.
  notes: ClinicalTrials.gov lists this as a combined Phase 1/2 study; mapped to PHASE_I because the schema accepts a single phase value.
- name: NCT04833907
  phase: PHASE_I
  status: ENROLLING_BY_INVITATION
  description: >
    Phase 1/2 open-label sequential-cohort study of a single intracranial dose
    of AVASPA/rAAV-Olig001-ASPA gene therapy for children with typical Canavan disease.
  target_phenotypes:
  - preferred_term: Hypomyelination
    term:
      id: HP:0003429
      label: CNS hypomyelination
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT04833907
    reference_title: "Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The latest generation AAV viral vector (rAAV-Olig001-ASPA) will be administered to patients using neurosurgical procedure which involves direct administration of gene therapy to affected regions of the brain."
    explanation: ClinicalTrials.gov records an intracranial oligodendrocyte-targeted ASPA gene-therapy trial for typical Canavan disease.
  notes: ClinicalTrials.gov lists this as a combined Phase 1/2 study; mapped to PHASE_I because the schema accepts a single phase value.
notes: >
  This curation uses ORPHA:141 as the direct disease mapping and integrates the
  Falcon deep-research report generated on 2026-05-03. The mechanistic model is
  centered on biallelic ASPA pathogenic variants, aspartoacylase deficiency,
  failure of NAA hydrolysis, NAA accumulation, reduced NAA-derived acetate for
  myelin lipid synthesis, oligodendrocyte maturation and myelination defects,
  spongiform leukodystrophy, and progressive neurodevelopmental impairment.
  Gene replacement and NAA-lowering strategies are marked as investigational,
  not established standard care.
references:
- reference: ORPHA:141
  title: Canavan disease
  findings: []
- reference: PMID:20301412
  title: Canavan Disease.
  tags:
  - GeneReviews
  findings: []
- reference: PMID:34011350
  title: "The natural history of Canavan disease: 23 new cases and comparison with patients from literature."
  found_in:
  - Canavan_Disease-deep-research-falcon.md
  findings: []
- reference: PMID:8412017
  title: "Canavan disease: biochemical and molecular studies."
  findings: []
- reference: PMID:15784740
  title: "Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease."
  findings: []
- reference: PMID:20637282
  title: Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
  findings: []
- reference: PMID:22617649
  title: Aspartoacylase supports oxidative energy metabolism during myelination.
  findings: []
- reference: PMID:28077719
  title: Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
  findings: []
- reference: PMID:28101991
  title: Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.
  findings: []
- reference: PMID:29456021
  title: Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
  findings: []
- reference: PMID:37601414
  title: Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation.
  found_in:
  - Canavan_Disease-deep-research-falcon.md
  findings: []
- reference: PMID:38582917
  title: Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.
  found_in:
  - Canavan_Disease-deep-research-falcon.md
  findings: []
- reference: PMID:12162821
  title: "Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain."
  found_in:
  - Canavan_Disease-deep-research-falcon.md
  findings: []
- reference: PMID:37755460
  title: Update on leukodystrophies and developing trials.
  found_in:
  - Canavan_Disease-deep-research-falcon.md
  findings: []
- reference: PMID:35187608
  title: "Canavan's spongiform leukodystrophy (Aspartoacylase deficiency) with emphasis on sonographic features in infancy: description of a case report and review of the literature."
  found_in:
  - Canavan_Disease-deep-research-falcon.md
  findings: []
- reference: PMID:38538326
  title: "Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease."
  found_in:
  - Canavan_Disease-deep-research-falcon.md
  findings: []
📚

References & Deep Research

References

16
ORPHA:141
Canavan disease
No top-level findings curated for this source.
PMID:20301412
Canavan Disease.
No top-level findings curated for this source.
PMID:34011350
The natural history of Canavan disease: 23 new cases and comparison with patients from literature.
No top-level findings curated for this source.
PMID:8412017
Canavan disease: biochemical and molecular studies.
No top-level findings curated for this source.
PMID:15784740
Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
No top-level findings curated for this source.
PMID:20637282
Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
No top-level findings curated for this source.
PMID:22617649
Aspartoacylase supports oxidative energy metabolism during myelination.
No top-level findings curated for this source.
PMID:28077719
Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
No top-level findings curated for this source.
PMID:28101991
Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.
No top-level findings curated for this source.
PMID:29456021
Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
No top-level findings curated for this source.
PMID:37601414
Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation.
No top-level findings curated for this source.
PMID:38582917
Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.
No top-level findings curated for this source.
PMID:12162821
Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
No top-level findings curated for this source.
PMID:37755460
Update on leukodystrophies and developing trials.
No top-level findings curated for this source.
PMID:35187608
Canavan's spongiform leukodystrophy (Aspartoacylase deficiency) with emphasis on sonographic features in infancy: description of a case report and review of the literature.
No top-level findings curated for this source.
PMID:38538326
Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Canavan Disease (Aspartoacylase deficiency) — Disease Characteristics Research Report
Edison Scientific Literature 29 citations 2026-05-03T10:35:32.242369

Canavan Disease (Aspartoacylase deficiency) — Disease Characteristics Research Report

Executive summary (current understanding)

Canavan disease (CD) is an ultra-rare, typically early-infantile onset leukodystrophy caused by biallelic loss-of-function variants in ASPA, leading to deficient aspartoacylase activity and pathologic accumulation of N-acetyl-L-aspartate (NAA), with characteristic spongiform degeneration/vacuolation and dys-/hypomyelination in CNS white matter. (bley2021thenaturalhistory pages 1-2, corti2023adenoassociatedvirusmediatedgene pages 1-2, grønbækthygesen2024cellularandmolecular pages 1-2)

1. Disease information

1.1 What is the disease?

Canavan disease is a severe neurodegenerative leukodystrophy characterized histologically by insufficient myelination with progressive spongy degeneration of brain white matter. (bley2021thenaturalhistory pages 1-2)

1.2 Key identifiers (cross-references)

  • OMIM/MIM (disease): MIM #271900 (bley2021thenaturalhistory pages 1-2)
  • OMIM (gene): ASPA (OMIM 608034) (matalon2002canavandiseaseprenatal pages 14-16)
  • ClinicalTrials.gov (active gene therapy trials): NCT04998396; NCT04833907 (NCT04998396 chunk 1, NCT04833907 chunk 1)
  • MONDO ID: Not identified in the retrieved primary literature corpus; should be added from MONDO/OMIM cross-reference during database integration (e.g., via MONDO registry). (no direct evidence in retrieved texts)

1.3 Synonyms / alternative names

  • Aspartoacylase deficiency (rossler2023canavan’sspongiformleukodystrophy pages 1-4)
  • Spongy degeneration of the CNS / spongiform leukodystrophy (rossler2023canavan’sspongiformleukodystrophy pages 1-4, matalon2002canavandiseaseprenatal pages 1-3)
  • N-acetylaspartic aciduria (sass2019aspartoacylasedeficiency(canavan pages 4-6)
  • Van Bogaert–Bertrand disease (janson2002clinicalprotocol.gene pages 1-2)

1.4 Evidence provenance (patient-level vs aggregated resources)

Evidence in this report is derived from a mix of (i) aggregated cohort natural history (23 cases plus literature comparison), (ii) individual case report/review, (iii) mechanistic review synthesizing multiple experimental studies, (iv) interventional trial protocols and expanded-access records, and (v) animal-model pathology studies. (bley2021thenaturalhistory pages 1-2, rossler2023canavan’sspongiformleukodystrophy pages 1-4, grønbækthygesen2024cellularandmolecular pages 1-2, NCT04998396 chunk 1, takeda2024myelinlesionin pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic cause (primary): Autosomal recessive biallelic pathogenic variants in ASPA leading to aspartoacylase deficiency, impaired NAA hydrolysis, and NAA accumulation in CNS. (matalon2002canavandiseaseprenatal pages 14-16, bley2021thenaturalhistory pages 1-2)

Mechanistic cause: ASPA normally hydrolyzes NAA to acetate and aspartate; ASPA deficiency leads to NAA accumulation and white matter pathology. (corti2023adenoassociatedvirusmediatedgene pages 1-2, grønbækthygesen2024cellularandmolecular pages 1-2)

2.2 Risk factors

  • Genetic risk factor: Being a carrier of an ASPA pathogenic variant; disease occurs in children with biallelic variants. (matalon2002canavandiseaseprenatal pages 14-16)
  • Population risk: Elevated carrier frequency estimates reported for Ashkenazi Jewish populations (range ~1/40 to 1/82). (matalon2002canavandiseaseprenatal pages 14-16)

2.3 Protective factors

No validated protective genetic or environmental factors were identified in the retrieved sources. (no direct evidence)

2.4 Gene–environment interactions

Recent mechanistic synthesis emphasizes that phenotype is a spectrum influenced by “genetic and environmental factors,” but specific gene–environment interaction mechanisms were not defined in the retrieved sources. (grønbækthygesen2024cellularandmolecular pages 7-8)

3. Phenotypes

3.1 Core clinical phenotypes (human)

Typical age of onset: “Onset of symptoms was between 0 and 6 months.” (bley2021thenaturalhistory pages 1-2)

Early hallmark phenotypes: Severe psychomotor disability and macrocephaly emerging in infancy (“Macrocephaly became apparent between 4 and 18 months of age”). (bley2021thenaturalhistory pages 1-2)

Common early manifestations (frequency from cohort): Within first 6 months, developmental delay (17/23), macrocephaly (12/23), abnormal eye movements (12/23). (bley2021thenaturalhistory pages 1-2)

Seizures: Rare in the first year but “increase in frequency over time,” with highest frequency toward end of first decade. (bley2021thenaturalhistory pages 1-2, bley2021thenaturalhistory pages 6-7)

Imaging-associated clinical trajectory: Progressive disease with early white matter edema/vacuolation that can progress toward atrophy/ventriculomegaly in later phases. (rossler2023canavan’sspongiformleukodystrophy pages 4-6)

3.2 Suggested HPO terms (examples; non-exhaustive)

  • Developmental delay — HP:0001263
  • Hypotonia — HP:0001252
  • Macrocephaly — HP:0000256
  • Abnormal eye movements / nystagmus — HP:0000639
  • Seizures — HP:0001250
  • Spasticity — HP:0001257
  • Leukodystrophy / abnormal white matter — HP:0002415

(bley2021thenaturalhistory pages 1-2, rossler2023canavan’sspongiformleukodystrophy pages 1-4, corti2023adenoassociatedvirusmediatedgene pages 1-2)

3.3 Quality-of-life impact

Formal QoL instruments (EQ-5D/SF-36/PROMIS) were not reported in the retrieved sources. Functional impact is substantial, with severe psychomotor disability and limited milestone acquisition. (bley2021thenaturalhistory pages 1-2, matalon2002canavandiseaseprenatal pages 1-3)

4. Genetic / molecular information

4.1 Causal gene

  • ASPA (aspartoacylase). Loss of ASPA activity causes Canavan disease. (matalon2002canavandiseaseprenatal pages 14-16, grønbækthygesen2024cellularandmolecular pages 1-2)

4.2 Pathogenic variant classes and molecular consequences

  • Loss-of-function is the dominant mechanism at the gene level. (matalon2002canavandiseaseprenatal pages 14-16)
  • A major contemporary concept is that many missense ASPA variants cause disease by protein destabilization → misfolding → protein quality control/proteasomal degradation, leading to reduced cellular abundance and functional enzyme loss. (grønbækthygesen2024cellularandmolecular pages 1-2, grønbækthygesen2024cellularandmolecular pages 21-22)

Direct abstract/review quotes supporting this concept: * The 2024 review states data “effectively categorize CD as a protein misfold- ing disorder (proteinopathy).” (grønbækthygesen2024cellularandmolecular pages 22-24)

4.3 Genotype–phenotype considerations / “mild” alleles

CD phenotypes are “better described as a spectrum of severity.” (grønbækthygesen2024cellularandmolecular pages 7-8)

The 2024 review notes candidate variants associated with milder presentations (reflecting residual activity/partial function), including R71H and Y288C among others. (grønbækthygesen2024cellularandmolecular pages 8-9)

4.4 Allele frequencies / population data

Carrier frequency in Ashkenazi Jewish populations has been estimated in the range ~1/40–1/82 (estimates vary by study and time). (matalon2002canavandiseaseprenatal pages 14-16)

4.5 Modifier genes / epigenetics

The natural history study observed that phenotype concordance among siblings but variability among individuals with identical mutations suggests unknown modifiers. (bley2021thenaturalhistory pages 1-2)

No specific modifier genes or epigenetic signatures were identified in the retrieved sources. (no direct evidence)

5. Environmental information

No established non-genetic environmental or lifestyle causal contributors were identified in the retrieved sources; CD is primarily a Mendelian metabolic leukodystrophy driven by ASPA deficiency. (matalon2002canavandiseaseprenatal pages 14-16, bley2021thenaturalhistory pages 1-2)

6. Mechanism / pathophysiology

6.1 Core causal chain (molecular → cellular → tissue → clinical)

  1. Trigger: Biallelic ASPA loss-of-function variants cause reduced/absent ASPA enzyme activity. (matalon2002canavandiseaseprenatal pages 14-16)
  2. Biochemical consequence: Failure to hydrolyze NAA → acetate + aspartate, causing NAA accumulation. (grønbækthygesen2024cellularandmolecular pages 1-2, corti2023adenoassociatedvirusmediatedgene pages 1-2)
  3. Cellular/tissue consequence: Oligodendrocyte dysfunction, hypomyelination/dysmyelination, and spongiform white-matter vacuolation. (corti2023adenoassociatedvirusmediatedgene pages 1-2, bley2021thenaturalhistory pages 1-2)
  4. Clinical consequence: Early-infantile onset progressive neurologic impairment, macrocephaly, psychomotor disability, and later seizures/spasticity. (bley2021thenaturalhistory pages 1-2, corti2023adenoassociatedvirusmediatedgene pages 1-2)

6.2 Pathway schematic (recent visual evidence)

A 2024 review figure provides a neuron–oligodendrocyte schematic of the NAA cycle and how ASPA deficiency disrupts NAA catabolism in Canavan disease. (grønbækthygesen2024cellularandmolecular media eaa25b8f)

6.3 Molecular mechanism of many missense variants (2024 concept)

The 2024 mechanistic review synthesizes high-throughput and computational evidence that many pathogenic ASPA variants reduce protein stability and abundance (fold destabilization), linking CD to proteostasis/PQC mechanisms and motivating potential small-molecule stabilizers or degradation blockers. (grønbækthygesen2024cellularandmolecular pages 21-22, grønbækthygesen2024cellularandmolecular pages 22-24)

6.4 Suggested ontology terms

GO biological processes (examples): * N-acetylaspartate metabolic process (supported conceptually by ASPA function) (grønbækthygesen2024cellularandmolecular pages 1-2) * Myelination / CNS myelination (bley2021thenaturalhistory pages 1-2, corti2023adenoassociatedvirusmediatedgene pages 1-2)

Cell types (CL examples): * Oligodendrocyte (central role; oligodendrocyte dysfunction highlighted) (corti2023adenoassociatedvirusmediatedgene pages 1-2, grønbækthygesen2024cellularandmolecular pages 1-2) * Astrocyte (astrocyte activation/gliosis in models) (takeda2024myelinlesionin pages 2-6)

7. Anatomical structures affected

7.1 Primary organs/systems

  • Central nervous system white matter (leukodystrophy; spongiform degeneration). (bley2021thenaturalhistory pages 1-2, rossler2023canavan’sspongiformleukodystrophy pages 1-4)

7.2 Imaging-anatomy patterns

MRI typically shows diffuse white matter involvement; the 2023 review notes frequent involvement of basal ganglia/thalami with overall widespread supratentorial and infratentorial white matter changes, and MRS shows an elevated NAA peak. (rossler2023canavan’sspongiformleukodystrophy pages 4-6)

7.3 Suggested UBERON terms (examples)

  • Brain white matter
  • Cerebral cortex
  • Brainstem

(rossler2023canavan’sspongiformleukodystrophy pages 4-6)

8. Temporal development

  • Onset: early infancy; often uneventful perinatal period. (bley2021thenaturalhistory pages 1-2)
  • Progression: progressive neurodevelopmental stagnation/decline; seizures increase over the first decade. (bley2021thenaturalhistory pages 6-7)
  • Critical window for intervention (inferred from early course): early diagnosis in the first 1–2 years is emphasized by natural history timing and by trial eligibility (most gene therapy protocols enroll infants/toddlers). (bley2021thenaturalhistory pages 1-2, NCT04998396 chunk 1, NCT04833907 chunk 1)

9. Inheritance and population

9.1 Inheritance

Autosomal recessive; carriers are asymptomatic. (matalon2002canavandiseaseprenatal pages 12-14)

9.2 Population distribution / founder effects

CD historically associated with Ashkenazi Jewish populations, but more recent cohorts note diagnoses “more frequently outside Ashkenazi Jewish communities than previously reported,” and many new diagnoses occur without known Ashkenazi ancestry. (bley2021thenaturalhistory pages 1-2, matalon2002canavandiseaseprenatal pages 14-16)

9.3 Prevalence/incidence

Quantitative prevalence/incidence estimates were not available in the retrieved evidence corpus (e.g., Orphanet registry data not retrieved). This is a gap for the knowledge base entry. (no direct evidence)

10. Diagnostics

10.1 Core diagnostic biomarkers and tests

Metabolite biomarker: Elevated NAA in urine/blood and/or brain. (bley2021thenaturalhistory pages 1-2)

Neuroimaging: MRI is the principal imaging tool; MR spectroscopy is diagnostically important because it shows a markedly elevated NAA peak. (rossler2023canavan’sspongiformleukodystrophy pages 1-4, rossler2023canavan’sspongiformleukodystrophy pages 4-6)

Genetic testing: Molecular confirmation by ASPA mutation analysis is part of standard diagnosis. (bley2021thenaturalhistory pages 1-2)

Direct quote (diagnostic statement): “CD is diagnosed by detection of elevated NAA in urine or blood or in brain by proton MR spectroscopy [...], as well as by ASPA mutation analysis.” (bley2021thenaturalhistory pages 1-2)

10.2 Screening (carrier/prenatal)

Because the disorder is autosomal recessive, carrier testing and prenatal/preimplantation genetic testing are feasible once familial variants are known. (matalon2002canavandiseaseprenatal pages 14-16, rossler2023canavan’sspongiformleukodystrophy pages 1-4)

11. Outcomes / prognosis

Earlier sources describe reduced survival and progressive disability, with severe early-onset forms often fatal in childhood/adolescence; cohort-level survival statistics are not comprehensively captured in the retrieved recent sources, but reduced life expectancy and progressive course are consistent across clinical descriptions. (matalon2002canavandiseaseprenatal pages 1-3, corti2023adenoassociatedvirusmediatedgene pages 1-2, rossler2023canavan’sspongiformleukodystrophy pages 1-4)

12. Treatment

12.1 Supportive care (standard of care)

No established curative therapy is cited in the retrieved sources; care is described as multidisciplinary and supportive (nutrition/feeding, seizure management, monitoring neurologic complications). (matalon2002canavandiseaseprenatal pages 1-3, matalon2002canavandiseaseprenatal pages 12-14)

MAXO suggestions (examples): * Seizure management * Nutritional support / enteral feeding * Physical therapy / rehabilitation

(matalon2002canavandiseaseprenatal pages 12-14)

12.2 Advanced therapeutics (2023–2024: gene therapy emphasis)

Key concept: Gene replacement is a rational approach because CD is a monogenic enzyme deficiency, and rAAV vectors (notably AAV9 and Olig001) are in active clinical development. (corti2023adenoassociatedvirusmediatedgene pages 1-2, ceravolo2024updateonleukodystrophies pages 8-10)

Real-world implementation (trial operations): Two major programs include a systemic AAV9 approach (BBP-812/CANaspire) and an intracerebroventricular oligodendrocyte-targeting approach (MYR-101/CAN-GT). (NCT04998396 chunk 1, NCT04833907 chunk 1)

Program/Trial name Vector/approach Route Phase/Study type Ages Key endpoints/biomarkers Source (with year, URL)
rAAV-Olig001-ASPA / MYR-101 (NCT04833907) Oligodendrocyte-targeting rAAV-Olig001 carrying ASPA; single-dose gene therapy Intracerebroventricular neurosurgical delivery to two predefined sites Phase 1/2, open-label interventional 3-60 months; cohorts: <15 mo, 15-36 mo, >36-60 mo Safety/AEs (CTCAE v5.0); cerebral myelination by SyMRI; brain NAA by MRS; CSF NAA; GMFM-88; Mullen Scales; spasticity; seizure/EEG (NCT04833907 chunk 1) ClinicalTrials.gov, 2021, https://clinicaltrials.gov/study/NCT04833907 (NCT04833907 chunk 1)
BBP-812 / CANaspire (NCT04998396) Recombinant AAV9 delivering human ASPA (BBP-812) Single IV infusion Phase 1/2, open-label interventional Up to 30 months Safety/AEs; urine NAA and CNS NAA by MRS to 12 months; GMFM-88; Bayley-4; Vineland-3; requires elevated urinary NAA and biallelic ASPA variants for entry (NCT04998396 chunk 1) ClinicalTrials.gov, 2021, https://clinicaltrials.gov/study/NCT04998396 (NCT04998396 chunk 1)
Single-patient IND (NCT05317780) rAAV9-CB6-ASPA with peri-vector immunomodulation (rituximab, sirolimus) Simultaneous IV + ICV Expanded access, open-label single-patient IND 18-24 months (single previously identified male child) Change from baseline in brain NAA, brain water content/morphology, clinical status, peripheral NAA; vector genomes in blood; immune responses to ASPA/AAV; routine safety labs (NCT05317780 chunk 1, corti2023adenoassociatedvirusmediatedgene pages 1-2) ClinicalTrials.gov, 2022, https://clinicaltrials.gov/study/NCT05317780 (NCT05317780 chunk 1)
AAV2-ASPA neurosurgical protocol Recombinant AAV2 carrying ASPA; direct gene transfer to affected brain regions Intraparenchymal neurosurgical brain delivery Clinical protocol / early interventional gene-therapy study Pediatric Canavan disease patients; protocol planned 21 patients Quantitative NAA in brain, blood, urine, CSF; MRI/MRS markers of myelination, water content, and morphology; neurological assessments (janson2002clinicalprotocol.gene pages 1-2) Janson et al., Human Gene Therapy, 2002, https://doi.org/10.1089/104303402760128612 (janson2002clinicalprotocol.gene pages 1-2)

Table: This table summarizes the main Canavan disease clinical gene therapy programs and studies identified in the evidence, including vector platform, route, study design, age ranges, and core biomarkers. It is useful for comparing how current and historical programs differ in delivery strategy and outcome measures.

Recent clinical report (2023): A published treated case used dual i.v. + i.c.v. rAAV9-CB6-ASPA with prophylactic immunomodulation; assessments included antibody monitoring, vector genomes by qPCR, imaging (MRI/DTI), and NAA measurements in CSF/brain by mass spectrometry and MRS. (corti2023adenoassociatedvirusmediatedgene pages 1-2)

MAXO suggestions (examples): * Gene therapy (AAV-mediated gene transfer) * Intracerebroventricular administration * Intravenous administration * Immunosuppressive therapy / immune modulation

(NCT04998396 chunk 1, NCT04833907 chunk 1, NCT05317780 chunk 1)

12.3 Expert opinion / analysis (authoritative synthesis)

The 2024 leukodystrophy trials review emphasizes that “gene therapy is emerging as a potential treatment avenue” for leukodystrophies and notes ongoing in vivo AAV ASPA programs for Canavan disease, while acknowledging the need for optimized delivery and adjunct approaches such as immunomodulation. (ceravolo2024updateonleukodystrophies pages 8-10)

13. Prevention

13.1 Primary prevention

Primary prevention is feasible through carrier screening in at-risk populations and family-based testing, given autosomal recessive inheritance and known carrier frequencies in some populations. (matalon2002canavandiseaseprenatal pages 14-16)

13.2 Secondary prevention

Early diagnosis using urine/blood NAA and MRI/MRS may allow earlier supportive interventions and eligibility for clinical trials with age-limited enrollment windows. (bley2021thenaturalhistory pages 1-2, NCT04998396 chunk 1)

13.3 Tertiary prevention

Multidisciplinary supportive care aims to reduce complications (nutrition/aspiration risk, seizure control). (matalon2002canavandiseaseprenatal pages 12-14)

14. Other species / natural disease

The retrieved evidence focuses on engineered rodent models; naturally occurring non-human disease was not identified in the retrieved corpus (outside mention of a naturally occurring “tremor rat” model with a large deletion including ASPA and other genes, complicating attribution). (grønbækthygesen2024cellularandmolecular pages 8-9)

15. Model organisms

15.1 Rat model (2024: Aspa knockout rat)

A TALEN-generated Aspa-knockout rat shows vacuolation with swollen axons, hypomyelination, and astrocyte activation, particularly in brainstem reticular formation and motor pathways, but notably did not show overt neurologic signs in the examined cohorts. (takeda2024myelinlesionin pages 1-2, takeda2024myelinlesionin pages 2-6)

15.2 Mouse and other rodent models (review synthesis)

Multiple Aspa mouse models and a “tremor rat” are described; engineered Aspa−/− mice can show macroencephaly, ataxia/tremor, seizures in some animals, and elevated urine NAA. (grønbækthygesen2024cellularandmolecular pages 8-9)

15.3 Model utility and limitations

  • Utility: Reproduces key CNS pathology (vacuolation/spongiform change, hypomyelination) for testing NAA/pathogenesis hypotheses and gene therapy. (takeda2024myelinlesionin pages 2-6, grønbækthygesen2024cellularandmolecular pages 8-9)
  • Limitation: Species/model differences in overt clinical phenotypes (e.g., rat model with strong histopathology but minimal early neurologic signs). (takeda2024myelinlesionin pages 1-2)

Key recent developments (prioritizing 2023–2024)

  1. Mechanistic reframing (2024): A 2024 ASPA-focused review synthesizes high-throughput and structural evidence indicating many ASPA missense variants act through folding destabilization and PQC-mediated degradation, with the explicit conclusion that data “effectively categorize CD as a protein misfold- ing disorder (proteinopathy).” (grønbækthygesen2024cellularandmolecular pages 22-24, grønbækthygesen2024cellularandmolecular pages 21-22)
  2. Clinical translation (2023): A published AAV9-ASPA gene therapy case report details dual-route delivery (i.v.+i.c.v.) and immunomodulation with multimodal biomarker tracking (NAA in CSF/brain, MRI/DTI). (corti2023adenoassociatedvirusmediatedgene pages 1-2)
  3. Active trials (2021–present, still current in 2023–2024 landscape): BBP-812 (AAV9, IV) and MYR-101 (Olig001, ICV) are ongoing/active programs with NAA (urine/CSF/brain) and myelination imaging as key pharmacodynamic endpoints. (NCT04998396 chunk 1, NCT04833907 chunk 1)
  4. New animal model (2024): A clean Aspa-knockout rat model provides a platform with human-like white-matter vacuolation/hypomyelination for mechanistic and therapeutic studies. (takeda2024myelinlesionin pages 1-2)

URLs and publication dates (selected key sources)

  • Grønbæk-Thygesen & Hartmann-Petersen. Cell & Bioscience. Apr 2024. https://doi.org/10.1186/s13578-024-01224-6 (grønbækthygesen2024cellularandmolecular pages 1-2)
  • Ceravolo et al. Journal of Neurology. Sep 2024. https://doi.org/10.1007/s00415-023-11996-5 (ceravolo2024updateonleukodystrophies pages 8-10)
  • Corti et al. Molecular Therapy – Methods & Clinical Development. Sep 2023. https://doi.org/10.1016/j.omtm.2023.06.001 (corti2023adenoassociatedvirusmediatedgene pages 1-2)
  • Rossler et al. Journal of Ultrasound. Feb 2023. https://doi.org/10.1007/s40477-022-00667-2 (rossler2023canavan’sspongiformleukodystrophy pages 1-4)
  • Takeda et al. Experimental Animals. Mar 2024. https://doi.org/10.1538/expanim.23-0089 (takeda2024myelinlesionin pages 1-2)
  • Bley et al. Orphanet Journal of Rare Diseases. May 2021. https://doi.org/10.1186/s13023-020-01659-3 (bley2021thenaturalhistory pages 1-2)
  • ClinicalTrials.gov: NCT04998396 (CANaspire/BBP-812). First posted 2021. https://clinicaltrials.gov/study/NCT04998396 (NCT04998396 chunk 1)
  • ClinicalTrials.gov: NCT04833907 (CAN-GT/MYR-101). First posted 2021. https://clinicaltrials.gov/study/NCT04833907 (NCT04833907 chunk 1)

Known gaps (not resolved in retrieved evidence set)

  • MONDO ID, ICD-10/ICD-11, MeSH identifiers were not present in the retrieved full-text/records; these should be populated from external ontology registries during integration. (no direct evidence)
  • Point prevalence/incidence values were not retrieved from Orphanet/registries in this tool run; should be added from Orphanet/GBD/national registries. (no direct evidence)

References

  1. (bley2021thenaturalhistory pages 1-2): Annette Bley, Jonas Denecke, Alfried Kohlschütter, Gerhard Schön, Sandra Hischke, Philipp Guder, Tatjana Bierhals, Heather Lau, Maja Hempel, and Florian S. Eichler. The natural history of canavan disease: 23 new cases and comparison with patients from literature. Orphanet Journal of Rare Diseases, May 2021. URL: https://doi.org/10.1186/s13023-020-01659-3, doi:10.1186/s13023-020-01659-3. This article has 54 citations and is from a peer-reviewed journal.

  2. (corti2023adenoassociatedvirusmediatedgene pages 1-2): Manuela Corti, Barry J. Byrne, Dominic J. Gessler, Grace Thompson, Samantha Norman, Jenna Lammers, Kirsten E. Coleman, Cristina Liberati, Melissa E. Elder, Maria L. Escolar, Ibrahim S. Tuna, Clementina Mesaros, Gary I. Kleiner, Deborah S. Barbouth, Heather L. Gray-Edwards, Nathalie Clement, Brian D. Cleaver, and Guangping Gao. Adeno-associated virus-mediated gene therapy in a patient with canavan disease using dual routes of administration and immune modulation. Molecular Therapy - Methods & Clinical Development, 30:303-314, Sep 2023. URL: https://doi.org/10.1016/j.omtm.2023.06.001, doi:10.1016/j.omtm.2023.06.001. This article has 30 citations.

  3. (grønbækthygesen2024cellularandmolecular pages 1-2): Martin Grønbæk-Thygesen and Rasmus Hartmann-Petersen. Cellular and molecular mechanisms of aspartoacylase and its role in canavan disease. Cell & Bioscience, Apr 2024. URL: https://doi.org/10.1186/s13578-024-01224-6, doi:10.1186/s13578-024-01224-6. This article has 12 citations and is from a peer-reviewed journal.

  4. (matalon2002canavandiseaseprenatal pages 14-16): Reuben Matalon and Kimberlee Michals Matalon. Canavan disease prenatal diagnosis and genetic counseling. Obstetrics and gynecology clinics of North America, 29 2:297-304, Jun 2002. URL: https://doi.org/10.1016/s0889-8545(01)00003-1, doi:10.1016/s0889-8545(01)00003-1. This article has 28 citations and is from a peer-reviewed journal.

  5. (NCT04998396 chunk 1): A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial). Aspa Therapeutics. 2021. ClinicalTrials.gov Identifier: NCT04998396

  6. (NCT04833907 chunk 1): rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease. Myrtelle Inc.. 2021. ClinicalTrials.gov Identifier: NCT04833907

  7. (rossler2023canavan’sspongiformleukodystrophy pages 1-4): Leon Rossler, Stefan Lemburg, Almut Weitkämper, Charlotte Thiels, Sabine Hoffjan, Huu Phuc Nguyen, Thomas Lücke, and Christoph M. Heyer. Canavan’s spongiform leukodystrophy (aspartoacylase deficiency) with emphasis on sonographic features in infancy: description of a case report and review of the literature. Journal of Ultrasound, 26:757-764, Feb 2023. URL: https://doi.org/10.1007/s40477-022-00667-2, doi:10.1007/s40477-022-00667-2. This article has 11 citations.

  8. (matalon2002canavandiseaseprenatal pages 1-3): Reuben Matalon and Kimberlee Michals Matalon. Canavan disease prenatal diagnosis and genetic counseling. Obstetrics and gynecology clinics of North America, 29 2:297-304, Jun 2002. URL: https://doi.org/10.1016/s0889-8545(01)00003-1, doi:10.1016/s0889-8545(01)00003-1. This article has 28 citations and is from a peer-reviewed journal.

  9. (sass2019aspartoacylasedeficiency(canavan pages 4-6): Jörn Oliver Sass and Ina Knerr. Aspartoacylase deficiency (canavan disease, n-acetylaspartic aciduria). Human Pathobiochemistry, pages 15-21, Mar 2019. URL: https://doi.org/10.1007/978-981-13-2977-7_2, doi:10.1007/978-981-13-2977-7_2. This article has 1 citations.

  10. (janson2002clinicalprotocol.gene pages 1-2): Christopher Janson, Scott McPhee, Larissa Bilaniuk, John Haselgrove, Mark Testaiuti, Andrew Freese, Dah-Jyuu Wang, David Shera, Peter Hurh, Joan Rupin, Elizabeth Saslow, Olga Goldfarb, Michael Goldberg, Ghassem Larijani, William Sharrar, Larisa Liouterman, Angelique Camp, Edwin Kolodny, Jude Samulski, and Paola Leone. Clinical protocol. gene therapy of canavan disease: aav-2 vector for neurosurgical delivery of aspartoacylase gene (aspa) to the human brain. Human gene therapy, 13 11:1391-412, Jul 2002. URL: https://doi.org/10.1089/104303402760128612, doi:10.1089/104303402760128612. This article has 329 citations and is from a peer-reviewed journal.

  11. (takeda2024myelinlesionin pages 1-2): Shuji Takeda, Rika Hoshiai, Miyuu Tanaka, Takeshi Izawa, Jyoji Yamate, Takashi Kuramoto, and Mitsuru Kuwamura. Myelin lesion in the aspartoacylase (aspa) knockout rat, an animal model for canavan disease. Experimental Animals, 73:347-356, Mar 2024. URL: https://doi.org/10.1538/expanim.23-0089, doi:10.1538/expanim.23-0089. This article has 0 citations and is from a peer-reviewed journal.

  12. (grønbækthygesen2024cellularandmolecular pages 7-8): Martin Grønbæk-Thygesen and Rasmus Hartmann-Petersen. Cellular and molecular mechanisms of aspartoacylase and its role in canavan disease. Cell & Bioscience, Apr 2024. URL: https://doi.org/10.1186/s13578-024-01224-6, doi:10.1186/s13578-024-01224-6. This article has 12 citations and is from a peer-reviewed journal.

  13. (bley2021thenaturalhistory pages 6-7): Annette Bley, Jonas Denecke, Alfried Kohlschütter, Gerhard Schön, Sandra Hischke, Philipp Guder, Tatjana Bierhals, Heather Lau, Maja Hempel, and Florian S. Eichler. The natural history of canavan disease: 23 new cases and comparison with patients from literature. Orphanet Journal of Rare Diseases, May 2021. URL: https://doi.org/10.1186/s13023-020-01659-3, doi:10.1186/s13023-020-01659-3. This article has 54 citations and is from a peer-reviewed journal.

  14. (rossler2023canavan’sspongiformleukodystrophy pages 4-6): Leon Rossler, Stefan Lemburg, Almut Weitkämper, Charlotte Thiels, Sabine Hoffjan, Huu Phuc Nguyen, Thomas Lücke, and Christoph M. Heyer. Canavan’s spongiform leukodystrophy (aspartoacylase deficiency) with emphasis on sonographic features in infancy: description of a case report and review of the literature. Journal of Ultrasound, 26:757-764, Feb 2023. URL: https://doi.org/10.1007/s40477-022-00667-2, doi:10.1007/s40477-022-00667-2. This article has 11 citations.

  15. (grønbækthygesen2024cellularandmolecular pages 21-22): Martin Grønbæk-Thygesen and Rasmus Hartmann-Petersen. Cellular and molecular mechanisms of aspartoacylase and its role in canavan disease. Cell & Bioscience, Apr 2024. URL: https://doi.org/10.1186/s13578-024-01224-6, doi:10.1186/s13578-024-01224-6. This article has 12 citations and is from a peer-reviewed journal.

  16. (grønbækthygesen2024cellularandmolecular pages 22-24): Martin Grønbæk-Thygesen and Rasmus Hartmann-Petersen. Cellular and molecular mechanisms of aspartoacylase and its role in canavan disease. Cell & Bioscience, Apr 2024. URL: https://doi.org/10.1186/s13578-024-01224-6, doi:10.1186/s13578-024-01224-6. This article has 12 citations and is from a peer-reviewed journal.

  17. (grønbækthygesen2024cellularandmolecular pages 8-9): Martin Grønbæk-Thygesen and Rasmus Hartmann-Petersen. Cellular and molecular mechanisms of aspartoacylase and its role in canavan disease. Cell & Bioscience, Apr 2024. URL: https://doi.org/10.1186/s13578-024-01224-6, doi:10.1186/s13578-024-01224-6. This article has 12 citations and is from a peer-reviewed journal.

  18. (grønbækthygesen2024cellularandmolecular media eaa25b8f): Martin Grønbæk-Thygesen and Rasmus Hartmann-Petersen. Cellular and molecular mechanisms of aspartoacylase and its role in canavan disease. Cell & Bioscience, Apr 2024. URL: https://doi.org/10.1186/s13578-024-01224-6, doi:10.1186/s13578-024-01224-6. This article has 12 citations and is from a peer-reviewed journal.

  19. (takeda2024myelinlesionin pages 2-6): Shuji Takeda, Rika Hoshiai, Miyuu Tanaka, Takeshi Izawa, Jyoji Yamate, Takashi Kuramoto, and Mitsuru Kuwamura. Myelin lesion in the aspartoacylase (aspa) knockout rat, an animal model for canavan disease. Experimental Animals, 73:347-356, Mar 2024. URL: https://doi.org/10.1538/expanim.23-0089, doi:10.1538/expanim.23-0089. This article has 0 citations and is from a peer-reviewed journal.

  20. (matalon2002canavandiseaseprenatal pages 12-14): Reuben Matalon and Kimberlee Michals Matalon. Canavan disease prenatal diagnosis and genetic counseling. Obstetrics and gynecology clinics of North America, 29 2:297-304, Jun 2002. URL: https://doi.org/10.1016/s0889-8545(01)00003-1, doi:10.1016/s0889-8545(01)00003-1. This article has 28 citations and is from a peer-reviewed journal.

  21. (ceravolo2024updateonleukodystrophies pages 8-10): Giorgia Ceravolo, Kristina Zhelcheska, Violetta Squadrito, David Pellerin, Eloisa Gitto, Louise Hartley, and Henry Houlden. Update on leukodystrophies and developing trials. Journal of Neurology, 271:593-605, Sep 2024. URL: https://doi.org/10.1007/s00415-023-11996-5, doi:10.1007/s00415-023-11996-5. This article has 18 citations and is from a domain leading peer-reviewed journal.

  22. (NCT05317780 chunk 1): Canavan-Single Patient IND. University of Florida. ClinicalTrials.gov Identifier: NCT05317780